Drug Profile


Alternative Names: AE 0047; Calbren; GJ 0956; Vatanidipine

Latest Information Update: 11 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Antihyperlipidaemics; Antihypertensives; Neuroprotectants
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Hypertension; Stroke

Most Recent Events

  • 31 Jan 2002 Discontinued - Preclinical for Atherosclerosis in Japan (unspecified route)
  • 31 Jan 2002 Discontinued - Preregistration for Hypertension in Japan (unspecified route)
  • 01 Oct 2001 Welfide Corporation merged with Mitsubishi-Tokyo Pharmaceuticals to form Mitsubishi Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top